A Randomized Controlled Phase 3 Study on the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Idiopathic Short Stature

Figures

• 

  Figure 1. Patient flow throughout the trial.

• 

  Figure 2. (A) HT-SDS, (B) height, (C) BA/CA, (D) HV, (E) ΔIGF-1 SDS, (F) PAH, (G) PAH stratified by age and, (H) HT-SDS for FSS and NFSS of the FAS at each evaluable time point. Δ, change in; BA, bone age; CA, chronological age; FAS, full analysis set; FSS, familial short stature; HT-SDS, height standard deviation score; HV, height velocity; IGFBP-3, insulin-like growth factor binding protein 3; IGF-1 SDS, insulin-like growth factor-1 standard deviation score; NFSS, nonfamilial short stature; PAH, predicted adult height; SD, standard deviation.